32^nd Euro Congress on Cancer Science & Therapy March 07-08, 2019 Barcelona, Spain

Douglas E Gladstone is an Associate Professor in the Department of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a Clinical Director of the Outpatient Bone Marrow Transplant Unit. In 2017, he led an educational program discussing how to lower donor specific antibodies to permissible levels for allogeneic bone marrow transplantation at the Annual American Society of Hematology conference

Medical Oncology

Jehad Zweiri, lecturer in Cancer studies at the University of Liverpool Medical School, born and grew up in Jordan and received his Bachelor’s degree from the University of Jordan in 1990. He obtained his master degree from London School of Hygiene and Tropical Medicine/University of London, and then obtained his PhD degree in 2000 from Kings College Medical School/University of London, in the field of Immune Gene Therapy of Cancer under the supervision of Professor Farzin Farzaneh. He then started his work as Postdoctoral Associate at the department of Immunology and Medicine at the University of Liverpool in 2002. In 2010 he was appointed as a lecturer in the university of Liverpool medical school and he is currently fellow of the British Higher Education Academy since 2012.

Cancer vaccines

Dr. Juan Pablo Marquez Manriquez, M.D. is a Medical Oncologist with training in Mexico, California and Seattle, Washington. His passion for Immunology and Oncology emerged from the very early stages of his life, as he prepared in pre-medicine by studying first Clinical Pharmacy and later medicine. He is currently developing projects for the prevention of gastrointestinal cancer in the CICS USA Seattle campus. He is currently specializing in the prevention of recurrence of tumors of high clinical impact such as ovarian, triple negative breast cancer, inflammatory breast cancer, colorectal and multiple myeloma. Since 2002, he has presented his scientific achievements at multiple international conferences led by AACR, ASCO, AAI, SITC and ESMO. He worked as a medical doctor at the Tumor Vaccine Group of the University of Washington. Dr. Marquez Manriquez is Binational Medical Director of the Binational Alliance in ImmunoOncology of Seattle, Sonora and Miami, including the Cancer Research Center in Sonora (CICS Sonora) both at the Ciudad Obregon Sonora campus and at the Seattle Washington campus (CICS USA), although his based in Seattle. In coordination with CICS and various institutions at the international level, CICS is developing through the investigations of Dr. Juan Pablo Marquez and CICS scientific medical team preventive vaccines to prevent pediatric and adult cancer and their recurrences.

Importantly he is focus on combo therapies including but not limited to multi peptide immunotherapy targeting clinically relevant targets such as Ape-1, Fascin, RCAS1, EGFR, Survivin, VCP, Bcl-2, etc. in refractory and progressive tumors. The Binational Immuno Oncology of Seattle, Sonora and Miami are also generating combination of therapies that will allow for longer remissions and fewer recurrences for different types of tumors such as ovarian, sarcomas, neurotumors and gastrointestinal tumors.

Dr. Bhattacharjee did her B.Sc in Biotechnology from Bangalore University in 2006 and M.Sc in Applied Genetics from Bangalore University in 2008. She then moved to England to pursue her DPhil (Phd) in Biochemistry from Oxford University where she studied the role of Fml1 and its partner proteins Mhf1 and Mhf2 in promoting genome stability. She was awarded her DPhil in 2012. During her time at Oxford, she was also a tutor at Greene’s College, Oxford. In 2013, Dr. Bhattacharjee moved to Cold Spring Harbor Laboratory, New York. At CSHL, her work has focused on understanding the epigenetic regulation of DNA repair.

Cancer Genomics

Dr. Georgia Zhuo Chen is currently Professor of Hematology and Medical Biology in Emory University. She received her Ph.D. from Louisiana State University, USA, in 1989. Dr. Chen has conducted research in the area of lung and head and neck cancers for over twenty-five years. Her research focuses on cancer metastasis, cancer prognostic biomarkers, anticancer therapeutic agents, and using nanotechnology in cancer research and clinic. Dr. Chen has received several awards from the US National Institutes of Health (NIH) as a PI since 1996. She has generated more than 150 publications in peer-reviewed journals and serves as an editorial board member for 5 journals. Dr. Chen received the NIH Career Development Award in 1998 and an award as a Georgia Cancer Coalition Distinguished Cancer Scholar in 2006.

cancer metastasis, cancer prognostic biomarkers, anticancer therapeutic agents, and using nanotechnology in cancer research

Alejandro Camacho Hernandez is a Hematologist Oncologist with training in Mexico, Mayo Clinic Rochester Minnesota, Massachusetts General Hospital and Arizona Cancer Center, USA. He became clinically speaking in expert in solid and hematological tumors microenvironment by manipulating with a cocktail of repurposing drugs the pro-tumors cells of the immune system such as Foxp3 positive cells, Th2, Th17, myeloid suppressor cells, etc. He is currently developing in Ciudad Obregon, several clinical pilot protocols to prevent multiple myeloma relapse and he already presented his preliminary data at ESMO 2015 in Vienna. He identified 14 biologically and clinically relevant proteins from multiple myeloma patients and now he designed 36 peptides containing CD8 and Th1 epitopes and according with his preliminarily data is very promising in combination with repurposing drugs of the tumor microenvironment. He works at the alliance in ImmunoOncology from Seattle and Sonora. He is also studying the potential role in prospective studies of patients with different types of tumors of the role of the platelets, coagulation factors and acute phase proteins in order to try at least five different drugs to combine with the standard of care treatment and look for clinical benefits either in PFS or OS

Solid and hematological tumors & Cancer Drugs

Martin Orlando Rosas Delgado has received his Medical degree from the University of Sonora campus Hermosillo. Currently he is a 3rd year CancerVac Fellow, and he is ready to start Internal Medicine and eventually Medical Oncology. During the past three years as CancerVac fellow he initially took one year of Clinical Oncology work on CICS Sonora, one year of clinically relevant work and now he is charge of the Ovarian Refractory Clinic in order to try to rescue to all the patients out of treatment with very interesting results. He performs all the clinical histories, clinical exploration, and analysis of the PET and CT scans in order to make correlations in coordination with other members of the group of his clinical and image observation with pathological and clinical laboratory and immunology parameters. He is currently performing his own project as part of his academic formation CancerVac fellow with potential positive clinical results in refractory ovary cancer patients. He is also actively involved in the training of the first year CancerVac fellows and he deliver several courses such as Medical Biochemistry, Oncology Radiology, Medical Immunology I and II, Principles of Internal Medicine and the application and importance of the clinically relevant research

Ovarian Cancer

Dr. Pedro Alejandro Lucero Diaz Doctor and researcher born in Lima, Peru. He received his degree in Medicine at the National University of San Marcos in Lima, Peru. He completed his specialty as a Medical Oncologist and Radiotherapist at the National Medical Center Siglo XXI, later he made his post-doctoral stay at the University of California Davis in the development of peptide vaccines and clinical immunomodulation under the supervision of Dr. José V. Torres. Dr. Lucero is a physician attached to the Medical Oncology Service of the Cancer Research Center in Sonora (CICS) in Ciudad Obregón. He is part of the medical team of the Advanced Molecular Oncology Clinic and is in charge of the Chemotherapy and Immunomodulation Unit with Immunogenic Chemotherapy. He is currently the Academic Coordinator of CICS; serves as a leader in a research project for the prevention of colon and pancreatic cancer in high-risk patients. Dr. Lucero has in the process publications in the area of ​​Molecular Oncology and Immunology of the gastric tract in patients with cancer in early and advanced stages.

Molecular Oncology and Immunology